INDIVIDUAL ARTICLE: Real-World Cases of Clascoterone Topical Treatment for Acne and Related Disorders.

IF 1.8 4区医学 Q3 DERMATOLOGY Journal of Drugs in Dermatology Pub Date : 2025-01-01 DOI:10.36849/JDD.73361

Charles Lynde, Sonya Abdulla, Anneke Andriessen, Sam Hanna, Fatemeh Jafarian, Monica Li, Jennifer Lipson, Andrei Metelitsa, Barbara Miedrzybrodzski, Elena Netchiporouk, MSc Jaggi Rao, Christopher Sibley, Jerry Tan

{"title":"INDIVIDUAL ARTICLE: Real-World Cases of Clascoterone Topical Treatment for Acne and Related Disorders.","authors":"Charles Lynde, Sonya Abdulla, Anneke Andriessen, Sam Hanna, Fatemeh Jafarian, Monica Li, Jennifer Lipson, Andrei Metelitsa, Barbara Miedrzybrodzski, Elena Netchiporouk, MSc Jaggi Rao, Christopher Sibley, Jerry Tan","doi":"10.36849/JDD.73361","DOIUrl":null,"url":null,"abstract":"<p><p>Acne vulgaris affects approximately 80% of young adults and adolescents in the world. Acne presents as comedones, pustules, papules, and nodules on the face, chest, shoulders, or back. It can lead to a significant decrease in quality of life with a high risk of associated depression and anxiety. Hyperstimulation of sebaceous glands by androgens play a pivotal role in acne pathogenesis. Clascoterone 1% cream is a first-in-class topical androgen receptor inhibitor approved for treatment of acne in patients 12 years and older. In the following real-world cases, expert dermatologists demonstrate use of clascoterone cream as monotherapy or in combination with other agents to treat acne in a variety of patients. Experts found that twice-daily use led to best overall results with patients. Real-world cases serve as invaluable guides for patients and dermatologists to help form personalized, targeted acne regimens. J Drugs Dermatol. 2025;24:1(Suppl 2):s3-10.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 1","pages":"73361s3-73361s14"},"PeriodicalIF":1.8000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drugs in Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36849/JDD.73361","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Acne vulgaris affects approximately 80% of young adults and adolescents in the world. Acne presents as comedones, pustules, papules, and nodules on the face, chest, shoulders, or back. It can lead to a significant decrease in quality of life with a high risk of associated depression and anxiety. Hyperstimulation of sebaceous glands by androgens play a pivotal role in acne pathogenesis. Clascoterone 1% cream is a first-in-class topical androgen receptor inhibitor approved for treatment of acne in patients 12 years and older. In the following real-world cases, expert dermatologists demonstrate use of clascoterone cream as monotherapy or in combination with other agents to treat acne in a variety of patients. Experts found that twice-daily use led to best overall results with patients. Real-world cases serve as invaluable guides for patients and dermatologists to help form personalized, targeted acne regimens. J Drugs Dermatol. 2025;24:1(Suppl 2):s3-10.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

个别文章：现实世界的情况下，Clascoterone局部治疗痤疮和相关疾病。

寻常性痤疮影响世界上大约80%的年轻人和青少年。痤疮表现为面部、胸部、肩部或背部的粉刺、脓疱、丘疹和结节。它会导致生活质量显著下降，并伴有抑郁和焦虑的高风险。雄激素对皮脂腺的过度刺激在痤疮的发病机制中起关键作用。1% Clascoterone乳膏是一种一流的外用雄激素受体抑制剂，被批准用于治疗12岁及以上患者的痤疮。在以下现实世界的案例中，皮肤科专家演示了使用clascoterone霜作为单一疗法或与其他药物联合治疗各种患者的痤疮。专家发现，每天服用两次对患者的总体效果最好。现实世界的案例为患者和皮肤科医生提供了宝贵的指导，帮助他们形成个性化的、有针对性的痤疮治疗方案。皮肤医学杂志，2025;24:1（增刊2）：53 -10。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Drugs in Dermatology DERMATOLOGY-

CiteScore

2.20

自引率

13.30%

发文量

289

审稿时长

3-6 weeks

期刊介绍： The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology. We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality. Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.